TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05961592: R-2487 in Patients With Rheumatoid Arthritis

Sponsor: Rise Therapeutics LLC · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 73 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$281,520

Rescue Site Savings

+$187,680

Unlock Full NCT05961592 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05961592 Rescue Dossier →